Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We are IMO so lucky to be in at these levels It boggles the mind.
It is not a PR it from an article.
Right Place At The Right Time
This Is Free To Fly And The News Pipeline Will Start To Flow. Very Excited To Be Part Of It. VTEQ
Smart Move Accumulate When The Opportunity Arises
I Am Going Long So I Have Time. If They Do Even 1 Million At These Prices Life Is Good For Me
The Estimate For 2014 Is $11 Million If They Do Half Of That I'm Fine With That Growth Takes Patience IMO
Veriteq (OTCQB:VTEQ) found itself in this enviable position just a few months ago and will continue to enjoy this luck for the near-term future. Because of an FDA ruling with an initial compliance deadline of October 2014, Veriteq will begin to enjoy mandated demand for its niche industry before October 2014 and has forecasted revenue of $239 million - many multiples of its current market capitalization - with 61% gross profit margins.
To summarize so far, Veriteq is the exclusive provider of the world's first FDA-cleared RFID device for on demand identification of medical devices that are implanted inside the human body. In other words, Veriteq sells a tiny $500 RFID chip that goes inside artificial joints and breast implants so they can be scanned by a doctor - even after decades of being inside the body. Doctors scan Veriteq's radio microchips from outside the body using Veriteq's hand-held scanner.
Veriteq's RFID microchips and hand-held readers are fully FDA approved. Its microchips are installed within medical devices so that manufacturing information can be recalled on demand, passively, through the skin using radio waves, in the event of an emergency like a product failure. Patients often lose product warranty cards, making paper-based identification unreliable in urgent medical situations. Veriteq's RFID microchip can never be lost, as it is implanted inside the medical device itself and always accessible from the hand-held reader at the point of care.
Veriteq has forecasted $11.5 million in breast implant revenue in 2014. Assume 50% of manufacturers buy Veriteq's product, no market growth whatsoever and no sales outside the U.S., Veriteq's forecasted $11.5 million in breast implant revenue calculates to $80.42 in revenue per procedure ($11.5M/50%/286000). Recall that Veriteq's microchip ultimately retails for $500 per procedure, so this forecast is found to be attainable at a 50% adoption rate.
Veriteq's Q.I.S.T. is the only FDA cleared UDI on the market that can give an implantable medical device manufacturer and healthcare provider the ability to retrieve UDI information about an implantable medical device in vivo, on demand, at the point of care, from outside the body. Currently, Veriteq knows of no other companies that can offer this type of solution to the medical device community
OP Is In The House Join The Fun Just Getting Going
Leaks Happen LOL
Some Know Exactly What Is Happening News Is Definetely Leaked
Overall, with just $6 million of easily serviceable debt, shares are uniquely undervalued given this near-term catalyst of the FDA's Class I compliance deadline this October. Veriteq's technology was cleared by the FDA in 2004 and is covered by dozens of U.S. patents, providing a strong barrier to entry against would-be competitors. Veriteq has experience delivering shareholder value, selling a RFID device five years ago to Stanley Black & Decker for $47.9 million. Veriteq's CEO was additionally responsible for leading a former company to a NASDAQ uplisting and has 15 years executive experience with technology companies. Silverman personally owns 5,462,770 shares of Veriteq common stock, squarely aligning his interests with shareholders.
Great Things Come To Those That Wait. We are Up 112% On 90+ Million Volume Today Alone This Will Build Very Rapidly. They Know Exactly What They Are Doing In Building Higher And Higher PPS. These Are Pro's In The Industry. Great PR's In The Last 60 Days And A Whole Lot More. Go VTEQ
The Chart Is Pure Stairway To Heaven.
And IMO This Is Just The Start. These Guys Invented The Technology 20 Years Ago. And Now They Are Not Restrained With The Non-Compete Agreements That They Had. Those Non Competes Have Expired And They Are Free To Go Nuts The Potential Pipeline Is Endless.
Insider Buy On August 25th Several PR'S In The Last Month. VTEQ Will Hit Silver Very Quick
The Contracts We Will See Going Forward Will Make A lot Of Heads Spin
I Remember The Dog Chip Too. That Division Was Sold To Stanley For 50 Million, Sweet Deal Great Technology. Welcome Aboard All.
New Mandate Will Help Sell Veriteq's FDA-Approved Microchip
Jan. 10, 2014 4:34 PM ET
Most companies are trying to sell products, but very few companies have the government mandating purchases in their product category. Veriteq (OTCQB:VTEQ) found itself in this enviable position just a few months ago and will continue to enjoy this luck for the near-term future. Because of an FDA ruling with an initial compliance deadline of October 2014, Veriteq will begin to enjoy mandated demand for its niche industry before October 2014 and has forecasted revenue of $239 million - many multiples of its current market capitalization - with 61% gross profit margins. Because of the immediate nature of Veriteq's first-to-market business, I have bought shares and am very optimistic about the first three quarters of 2014. Below, I discuss my investment rationale and the real risks of Veriteq failing to accomplish its revenue goals.
To summarize so far, Veriteq is the exclusive provider of the world's first FDA-cleared RFID device for on demand identification of medical devices that are implanted inside the human body. In other words, Veriteq sells a tiny $500 RFID chip that goes inside artificial joints and breast implants so they can be scanned by a doctor - even after decades of being inside the body. Doctors scan Veriteq's radio microchips from outside the body using Veriteq's hand-held scanner.
Veriteq's RFID microchips and hand-held readers are fully FDA approved. Its microchips are installed within medical devices so that manufacturing information can be recalled on demand, passively, through the skin using radio waves, in the event of an emergency like a product failure. Patients often lose product warranty cards, making paper-based identification unreliable in urgent medical situations. Veriteq's RFID microchip can never be lost, as it is implanted inside the medical device itself and always accessible from the hand-held reader at the point of care.
You might be wondering why a would doctor need to scan a device years after surgery. In France in 2010, a manufacturer of breast implants named PIP used industrial-grade silicone instead of medical-grade in its implants. As a result, PIP implants had double the rupture rate versus other implants, and patients grew very concerned that they may have had PIP's implants inside of their bodies. Unfortunately, many of these patients had no idea who the manufacturers of their implants were, did not have their product or warranty cards, and their plastic surgeons did not have records. This uncertainty lead to understandable panic among patients.
FDA Steps In
In response to growing concern about product failures and anonymous medical devices in the U.S., the FDA proposed a rule on July 10, 2012, requiring medical device manufacturers to adopt a uniform identification system for their products. On September 20, 2013, the FDA finalized this rule reflected in § 801.50 requiring medical device makers to comply with its Unique Device Identification system (UDI). This FDA Final Rule for UDI requires manufacturers to disclose the product's lot or batch number, expiration date, and manufacturing date, as well as link this information through the product's UDI number to a searchable database administered by the government. Rapid access to data like a serial number could be potentially lifesaving in the event of a product recall or when an adverse event report is issued by the FDA.
No personally identifiable patient information will be stored in this database. UDI numbers will simply serve as a way to retrieve manufacturing details in the event of emergencies like product defects or recalls. Many other countries are joining the FDA by creating similar systems, such as England's statute expected to pass legislative approval by late 2014.
The FDA has scheduled deadlines for UDI compliance.
Class III medical devices (high risk) by October 2014
Class II medical devices (moderate risk) by October 2016
Class I medical devices (low risk) by October 2018
Catalyst: October 2014 Deadline
VeriTeQ OTC VTEQ News Stream Spectacular
DELRAY BEACH, Fla.--(BUSINESS WIRE)Jan 8, 2014 - VeriTeQ Endorses England's Decision to Launch Breast Implant Registry--VeriTeQ Corporation (“VeriTeQ”) (OTC Markets: VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that a new breast implant registry will be launched in England beginning early this year to track breast implant procedures performed in the country. Health ministers in Wales, Scotland and Northern Ireland will also be encouraged to join the register.
Health ministers in England are expected to announce the launch of the pilot registry this month, and legislation to make it a statutory requirement is expected later this year. The cosmetic procedures market in the UK totaled £750m in 2005, and reached £2.3bn in 2010. It is forecast to reach £3.6bn by 2015.
VeriTeQ’s FDA cleared Q Inside Safety Technology™ acts as an electronic serial number to enable physicians and patients to access a secure online database to retrieve implant-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data. Q Inside Safety Technology can be the technology option to aid the registry by providing accurate device identification that cannot be lost or entered incorrectly into a patient’s electronic health record.
Following the Poly Implant Prothese (“PIP”) scandal that occurred throughout the EU in which tens of thousands of women received defective breast implan Following the Poly Implant Prothese (“PIP”) scandal that occurred throughout the EU in which tens of thousands of women received defective breast implants, legislators and the healthcare community are focused on improving healthcare records and device traceability through a mandated registry, much like the registry currently used to record hip and knee surgeries.
“We have continually pronounced our belief that all medical devices should be able to be identified non-invasively from within the body, without the need to explant a device, in the event of a safety issue or recall,” said Scott R. Silverman, Chairman and CEO of VeriTeQ. “The PIP scare is an unfortunate yet perfect example of why it is critical for this type of accurate device identification. There are still many women in the EU who do not know that they received PIP implants, which carry a significantly higher chance of rupture.”
DELRAY BEACH, Fla., Sep 16, 2014 (BUSINESS WIRE) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets: VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that more than 1,000 women worldwide have now received Motiva Implant Matrix(R) breast implants with VeriTeQ's Q Inside Safety Technology(TM). Motiva Implant Matrix(R) breast implants, manufactured by Establishment Labs S.A. ("EL"), featuring VeriTeQ's Q Inside Safety Technology(TM) can be safely and accurately identified from outside of the body in a physician's office.
VeriTeQ's FDA cleared Q Inside Safety Technology(TM) acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients access to secure online databases to retrieve device-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer. Q Inside Safety Technology(TM) may also provide an extra level of protection to the patient in the event of a recall or other safety event.
EL's Motiva Implant Matrix(R) Ergonomix(TM), VelvetSurface(R) PLUS, and SilkSurface(R) PLUS, all with VeriTeQ's Q Inside Safety Technology, have received CE Mark approval.
"This is an important milestone for Motiva and a clear signal to the industry that women value innovation and safety in long-term implantable devices," said Juan Jose Chacon-Quiros, Chief Executive Officer of EL.
"We are very proud of the work we are doing with our partner Establishment Labs to reach this significant milestone for our medical device identification business," said Scott R. Silverman, VeriTeQ's Chairman and Chief Executive Officer. "EL continues to see increased demand for its best-in-class breast implants as both physicians and patients request enhanced identification and other advanced technology options for their medical devices.
DELRAY BEACH, Fla., Sep 18, 2014 (GLOBE NEWSWIRE via COMTEX) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has unveiled two new readers used to identify VeriTeQ's Q Inside Safety Technology(TM) within implantable medical devices: the Q Inside Reader + and the Q Inside Reader XR +. The new readers are being launched based on demand from the breast implant industry.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=27730
The readers will identify VeriTeQ's Q Inside Safety Technology micro-transponders used for unique medical device identification. The Q Inside Reader + is Bluetooth-enabled and comes complete with a USB lead for charging the reader's internal rechargeable battery. The Q Inside Reader XR + is also Bluetooth-enabled and has an extended read-range.
VeriTeQ's FDA cleared Q Inside Safety Technology(TM) acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients access to secure online databases to retrieve device-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer. Q Inside Safety Technology(TM) may also provide an extra level of protection to the patient in the event of a recall or other safety event.
"Feedback from our customers and technology innovation has always been a vital part of our business, so we felt it was necessary to evolve our product offerings to meet the demands of those who are critical to our growth," said Scott R. Silverman, VeriTeQ's Chairman and Chief Executive Officer. "The new Q Inside readers are compact and easy-to-use, with a look and feel that better represents the aesthetic of the industry we serve."
DELRAY BEACH, Fla., Sep 29, 2014 (GLOBE NEWSWIRE via COMTEX) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has received an order for 100 units of its new Q Inside readers for breast implants. The Q Inside reader identifies VeriTeQ's Q Inside Safety Technology within breast implants and other medical devices.
VeriTeQ recently announced the launch of its new readers, the Q Inside Reader + and the Q Inside Reader XR +, which identify its Q Inside Safety Technology(TM) micro-transponders used for unique medical device identification. VeriTeQ's FDA cleared Q Inside Safety Technology(TM) acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients access to secure online databases to retrieve device-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer.
Commenting on the order, Scott R. Silverman, VeriTeQ's Chairman and CEO, stated, "We continue to evolve our technology on a customer-by-customer basis to meet unique needs and technology desires. Our new Q Inside reader is just an example of how we meet our customer's needs with new and enhanced design."
DELRAY BEACH, Fla., Oct 09, 2014 (GLOBE NEWSWIRE via COMTEX) -- VeriTeQ Corporation ("VeriTeQ" or "Company") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has entered an agreement providing an exclusive license of multiple patents from North Carolina State University ("NCSU"). VeriTeQ will license 24 patents, which are the foundation for its FDA cleared Q Inside SmartMarker and OneDose products for radiation dosimetry.
Q Inside SmartMarker (formerly known as DVS SmartMarker) is an implantable radiation sensor for use in breast and prostate cancer patients undergoing photon external beam treatments. It is implanted in, or adjacent to, solid-mass tumors and gathers data on the actual dose of radiation being delivered to the tumor and surrounding normal tissue. Q Inside SmartMarker is intended to be used in the balancing between delivering maximum dose to the tumor while minimizing the impact to healthy tissue. The sensor can confirm the treatment is conforming to the physician's plan, as even a small deviation from the planned dose can have a significant impact on patient survival rates.
VeriTeQ's OneDose external radiation sensing system is FDA cleared for use in patients being treated with external beam radiation. OneDose is a proprietary, wearable, single-use system that is used to verify radiation oncology doses quickly and conveniently. The OneDose system is comprised of disposable sensors that attach to the patient's skin using a basic adhesive and a scanner that reads the sensor. VeriTeQ believes OneDose is the only wireless, pre-calibrated, disposable, skin surface sensor that provides instant dose delivery data, which could be fed into patient radiology reports and health records.
"Expanding our relationship with NCSU not only helps strengthen our intellectual property portfolio, but, we believe, also better positions us to commercialize these important radiation measurement products through the benefit of a direct relationship with the source of the core science," said Scott R. Silverman, VeriTeQ's Chairman and Chief Executive Officer. "Our team is highly focused on returning to market Q Inside SmartMarker and One Dose, which were previously used in numerous hospitals in the U.S. to help prevent radiation overdose."
The patents in questions were previously being made available to VeriTeQ through a sublicense agreement. The new, direct agreement with NCSU is effective immediately.
Thats The Beauty NO SHARES Very Quick Mover
The More DD The Better It Looks. The Volume Is Screaming
Any We Know Several Thousand Percent Is Doable Here Go VTEQ
DELRAY BEACH, Fla., Oct 15, 2014 (GLOBE NEWSWIRE via COMTEX) -- VeriTeQ Corporation ("VeriTeQ" or "Company") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that the Company and its breast implant customer, Establishment Labs, S.A., ("EL") are hosting a physician conference in Salzburg, Austria on October 16, 2014, based on demand for EL's Motiva Implant Matrix(R) breast implants with VeriTeQ's Q Inside Safety Technology(TM).
As of mid-September, more than 1,000 women in Europe, Latin America and Asia have now received Motiva Implant Matrix(R) breast implants with Q Inside Safety Technology(TM). EL's Motiva Implant Matrix(R) Ergonomix(TM), VelvetSurface(R) PLUS, and SilkSurface(R) PLUS, all with VeriTeQ's Q Inside Safety Technology(TM), have received CE Mark approval.
VeriTeQ's FDA cleared Q Inside Safety Technology(TM) acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients access to secure online databases to retrieve device-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer. Q Inside Safety Technology(TM) may also provide an extra level of protection to the patient in the event of a recall or other safety event.
"In conjunction with VeriTeQ, we have advanced Motiva breast implant technology to the 21 century," said EL's Chief Executive Officer Juan Jose Chacon-Quiros. "Patients and physicians are now able to choose our innovative products for enhanced safety and satisfaction."
The educational conference for plastic, aesthetic and reconstructive surgeons is being held at the Kavalierhaus Klessheim in Salzburg, Austria.
DELRAY BEACH, Fla., Oct 09, 2014 (GLOBE NEWSWIRE via COMTEX) -- VeriTeQ Corporation ("VeriTeQ" or "Company") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has entered an agreement providing an exclusive license of multiple patents from North Carolina State University ("NCSU"). VeriTeQ will license 24 patents, which are the foundation for its FDA cleared Q Inside SmartMarker and OneDose products for radiation dosimetry.
Q Inside SmartMarker (formerly known as DVS SmartMarker) is an implantable radiation sensor for use in breast and prostate cancer patients undergoing photon external beam treatments. It is implanted in, or adjacent to, solid-mass tumors and gathers data on the actual dose of radiation being delivered to the tumor and surrounding normal tissue. Q Inside SmartMarker is intended to be used in the balancing between delivering maximum dose to the tumor while minimizing the impact to healthy tissue. The sensor can confirm the treatment is conforming to the physician's plan, as even a small deviation from the planned dose can have a significant impact on patient survival rates.
VeriTeQ's OneDose external radiation sensing system is FDA cleared for use in patients being treated with external beam radiation. OneDose is a proprietary, wearable, single-use system that is used to verify radiation oncology doses quickly and conveniently. The OneDose system is comprised of disposable sensors that attach to the patient's skin using a basic adhesive and a scanner that reads the sensor. VeriTeQ believes OneDose is the only wireless, pre-calibrated, disposable, skin surface sensor that provides instant dose delivery data, which could be fed into patient radiology reports and health records.
"Expanding our relationship with NCSU not only helps strengthen our intellectual property portfolio, but, we believe, also better positions us to commercialize these important radiation measurement products through the benefit of a direct relationship with the source of the core science," said Scott R. Silverman, VeriTeQ's Chairman and Chief Executive Officer. "Our team is highly focused on returning to market Q Inside SmartMarker and One Dose, which were previously used in numerous hospitals in the U.S. to help prevent radiation overdose."
The patents in questions were previously being made available to VeriTeQ through a sublicense agreement. The new, direct agreement with NCSU is effective immediately.
DELRAY BEACH, Fla., Sep 29, 2014 (GLOBE NEWSWIRE via COMTEX) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has received an order for 100 units of its new Q Inside readers for breast implants. The Q Inside reader identifies VeriTeQ's Q Inside Safety Technology within breast implants and other medical devices.
VeriTeQ recently announced the launch of its new readers, the Q Inside Reader + and the Q Inside Reader XR +, which identify its Q Inside Safety Technology(TM) micro-transponders used for unique medical device identification. VeriTeQ's FDA cleared Q Inside Safety Technology(TM) acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients access to secure online databases to retrieve device-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer.
Commenting on the order, Scott R. Silverman, VeriTeQ's Chairman and CEO, stated, "We continue to evolve our technology on a customer-by-customer basis to meet unique needs and technology desires. Our new Q Inside reader is just an example of how we meet our customer's needs with new and enhanced design."
DELRAY BEACH, Fla., Sep 18, 2014 (GLOBE NEWSWIRE via COMTEX) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has unveiled two new readers used to identify VeriTeQ's Q Inside Safety Technology(TM) within implantable medical devices: the Q Inside Reader + and the Q Inside Reader XR +. The new readers are being launched based on demand from the breast implant industry.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=27730
The readers will identify VeriTeQ's Q Inside Safety Technology micro-transponders used for unique medical device identification. The Q Inside Reader + is Bluetooth-enabled and comes complete with a USB lead for charging the reader's internal rechargeable battery. The Q Inside Reader XR + is also Bluetooth-enabled and has an extended read-range.
VeriTeQ's FDA cleared Q Inside Safety Technology(TM) acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients access to secure online databases to retrieve device-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer. Q Inside Safety Technology(TM) may also provide an extra level of protection to the patient in the event of a recall or other safety event.
"Feedback from our customers and technology innovation has always been a vital part of our business, so we felt it was necessary to evolve our product offerings to meet the demands of those who are critical to our growth," said Scott R. Silverman, VeriTeQ's Chairman and Chief Executive Officer. "The new Q Inside readers are compact and easy-to-use, with a look and feel that better represents the aesthetic of the industry we serve."
DELRAY BEACH, Fla., Sep 16, 2014 (BUSINESS WIRE) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets: VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that more than 1,000 women worldwide have now received Motiva Implant Matrix(R) breast implants with VeriTeQ's Q Inside Safety Technology(TM). Motiva Implant Matrix(R) breast implants, manufactured by Establishment Labs S.A. ("EL"), featuring VeriTeQ's Q Inside Safety Technology(TM) can be safely and accurately identified from outside of the body in a physician's office.
VeriTeQ's FDA cleared Q Inside Safety Technology(TM) acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients access to secure online databases to retrieve device-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer. Q Inside Safety Technology(TM) may also provide an extra level of protection to the patient in the event of a recall or other safety event.
EL's Motiva Implant Matrix(R) Ergonomix(TM), VelvetSurface(R) PLUS, and SilkSurface(R) PLUS, all with VeriTeQ's Q Inside Safety Technology, have received CE Mark approval.
"This is an important milestone for Motiva and a clear signal to the industry that women value innovation and safety in long-term implantable devices," said Juan Jose Chacon-Quiros, Chief Executive Officer of EL.
"We are very proud of the work we are doing with our partner Establishment Labs to reach this significant milestone for our medical device identification business," said Scott R. Silverman, VeriTeQ's Chairman and Chief Executive Officer. "EL continues to see increased demand for its best-in-class breast implants as both physicians and patients request enhanced identification and other advanced technology options for their medical devices.
The Possibilities With The Technology Are Endless. You May Be Right As Soon As It Dips Someone Eats Them Up
LOL The NUTS Are Hungry. Now I Know I am In The Right Place
LOL I Have About 40 Tabs Open It May Be Not Sure
Looks Like The Latest 8k Shows Funding Through 2015. I may Be Wrong Still Doing DD
I Don't See Any Dilution It Appears To Be 63 Million And 52 Million In The Float. Am I Wrong.
Thats What The Last Quarterly Says. WOW How Is This Company Under A $5 Not Pumping Just Curious. Damn
VTEQ Unbelievable 63 Million Shares Is That Right??
VTEQ Could Be Dollar Land. .70 Six Months Ago. Insiders Buying
This Company Is Hidden Gem. Found It Yesterday. WOW VTEQ
They never should have buried the PR. SMH Why would you release a PR on a Friday Night. Step Number 1 Fire The Investor Relations Company
It is a 2 Star General and 10 Others in Quarantine